Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen
| Autor: | Noppawan Piaseu, R. Rajatanavin, S. Sae Tung, Boonsong Ongphiphadhanakul, La-or Chailurkit |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Bone disease Calcitriol medicine.drug_class Osteoporosis chemistry.chemical_element Medrogestone Calcium General Biochemistry Genetics and Molecular Biology chemistry.chemical_compound Absorptiometry Photon Bone Density Internal medicine Humans Medicine Osteoporosis Postmenopausal Femoral neck Estrogens Conjugated (USP) Lumbar Vertebrae Progesterone Congeners Femur Neck business.industry Estrogen Replacement Therapy Obstetrics and Gynecology Middle Aged Thailand medicine.disease Postmenopause Menopause Calcium Channel Agonists Endocrinology medicine.anatomical_structure chemistry Estrogen Female business Follow-Up Studies medicine.drug |
| Zdroj: | Maturitas. 34:179-184 |
| ISSN: | 0378-5122 |
| DOI: | 10.1016/s0378-5122(99)00091-2 |
| Popis: | Estrogen deficiency is the most common cause of postmenopausal osteoporosis and estrogen replacement is well known to retard postmenopausal bone loss. Calcium supplement alone is generally considered to be insufficient for the prevention of bone loss associated with estrogen deficiency while the role of calcitriol is unclear. In the present study we examined the efficacy different doses of estrogen or calcitriol in the prevention of postmenopausal bone loss in Thais.The subjects consisted of 146 Thai women no more than 6 years postmenopausal. The subjects were randomly allocated to receive 750 mg supplemental calcium alone, calcium and conjugated equine estrogen (CEE) at 0.3 or 0.625 mg, calcium and calcitriol at 0.25 or 0.5 microg daily. Those receiving CEE also took 5 mg medrogestone for 12 days each month. BMD at L2-4 and femoral neck were measured at baseline 1 year and 2 years after treatments. Data were expressed as mean +/- S.E.Subjects on supplemental calcium alone had approximately 2.5% decreases in L2-4 (P0.05) and femoral BMD (P0.01) at 2 years. CEE (0.3 mg) resulted in 3.20 +/- 1.2% increase in vertebral BMD (P0.05) while no significant change in BMD was demonstrated at the femoral neck. Likewise, 0.625 mg of CEE induced 5.4 +/- 1.4% increase in vertebral BMD at 2 years (P0.001) without change in the femoral BMD. In regard to calcitriol, no significant change in vertebral or femoral BMD was demonstrated with either 0.25 or 0.5 microg calcitriol.We concluded that calcitriol is effective in the prevention of early postmenopausal bone loss in Thais. It represents an option for the prevention of osteoporosis in postmenopausal women who are contraindicated for estrogen replacement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect